메뉴 건너뛰기




Volumn 57, Issue 18, 2014, Pages 7550-7564

Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; ANTIRHEUMATIC AGENT; BMS 817399; CHEMOKINE RECEPTOR CCR1; PREGNANE X RECEPTOR; RIFAMPICIN; UNCLASSIFIED DRUG; UREA; 1-(1-(4-(4-CHLOROPHENYL)-4-HYDROXY-3,3-DIMETHYLPIPERIDIN-1-YL)-3-METHYL-1-OXOBUTAN-2-YL)-3-(2-HYDROXY-2-METHYLPROPYL)UREA; PIPERIDINE DERIVATIVE; STEROID RECEPTOR; VALINE;

EID: 84907452532     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5003167     Document Type: Article
Times cited : (41)

References (44)
  • 1
    • 34247855761 scopus 로고    scopus 로고
    • Chemokine: Receptor structure, interactions, and antagonism
    • Allen, S. J.; Crown, S. E.; Handel, T. M. Chemokine: receptor structure, interactions, and antagonism Annu. Rev. Immunol. 2007, 25, 787-820
    • (2007) Annu. Rev. Immunol. , vol.25 , pp. 787-820
    • Allen, S.J.1    Crown, S.E.2    Handel, T.M.3
  • 4
    • 58849121854 scopus 로고    scopus 로고
    • Chemokine receptor CCR1 regulates inflammatory cell infiltration after renal ischemia-reperfusion injury
    • Furuichi, K.; Gao, J.-L.; Horuk, R.; Wada, T.; Kaneko, S.; Murphy, P. M. Chemokine receptor CCR1 regulates inflammatory cell infiltration after renal ischemia-reperfusion injury J. Immunol. 2008, 181, 8670-8676
    • (2008) J. Immunol. , vol.181 , pp. 8670-8676
    • Furuichi, K.1    Gao, J.-L.2    Horuk, R.3    Wada, T.4    Kaneko, S.5    Murphy, P.M.6
  • 5
    • 79955476625 scopus 로고    scopus 로고
    • Overcoming hurdles in developing successful drugs targeting chemokine receptors
    • Schall, T. J.; Proudfoot, A. E. Overcoming hurdles in developing successful drugs targeting chemokine receptors Nat. Rev. Immunol. 2011, 11, 355-363
    • (2011) Nat. Rev. Immunol. , vol.11 , pp. 355-363
    • Schall, T.J.1    Proudfoot, A.E.2
  • 6
    • 80054935464 scopus 로고    scopus 로고
    • Targeting CCR1
    • Smit, M. J. Lira, S. A. Leurs, R. Wiley-VCH: Weinheim, Germany
    • Horuk, R. Targeting CCR1. Chemokine Receptors as Drug Targets; Smit, M. J.; Lira, S. A.; Leurs, R., Eds.; Wiley-VCH: Weinheim, Germany, 2011; pp 323-338.
    • (2011) Chemokine Receptors As Drug Targets , pp. 323-338
    • Horuk, R.1
  • 8
    • 77955631528 scopus 로고    scopus 로고
    • CCR1 antagonists: What have we learned from clinical trials
    • Gladue, R. P.; Brown, M. F.; Zwillich, S. H. CCR1 antagonists: what have we learned from clinical trials Curr. Top. Med. Chem. 2010, 10, 1268-1277
    • (2010) Curr. Top. Med. Chem. , vol.10 , pp. 1268-1277
    • Gladue, R.P.1    Brown, M.F.2    Zwillich, S.H.3
  • 9
    • 77958457972 scopus 로고    scopus 로고
    • N-aryl pyrazoles, indazoles and azaindazoles as antagonists of CC chemokine receptor 1: Patent cooperation treaty applications WO2010/036632, WO2009/134666 and WO2009/137338
    • Carter, P. H.; Hynes, J. N-aryl pyrazoles, indazoles and azaindazoles as antagonists of CC chemokine receptor 1: patent cooperation treaty applications WO2010/036632, WO2009/134666 and WO2009/137338 Expert Opin. Ther. Pat. 2010, 20, 1609-1618
    • (2010) Expert Opin. Ther. Pat. , vol.20 , pp. 1609-1618
    • Carter, P.H.1    Hynes, J.2
  • 14
    • 0037660976 scopus 로고    scopus 로고
    • Chemokine blockade and chronic inflammatory disease: Proof of concept in patients with rheumatoid arthritis
    • It is inferred by the authors and others (ref 18) that CP-481715 is the compound employed in the following study
    • It is inferred by the authors and others (ref 18) that CP-481715 is the compound employed in the following study: Haringman, J. J.; Kraan, M. C.; Smeets, T. J. M.; Zwinderman, A. H.; Tak, P. P. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis Ann. Rheum. Dis. 2003, 62, 715-721
    • (2003) Ann. Rheum. Dis. , vol.62 , pp. 715-721
    • Haringman, J.J.1    Kraan, M.C.2    Smeets, T.J.M.3    Zwinderman, A.H.4    Tak, P.P.5
  • 15
    • 53149105176 scopus 로고    scopus 로고
    • Evaluation of the effect of the specific CCR1 antagonist CP-481715 on the clinical and cellular responses observed following epicutaneous nickel challenge in human subjects
    • Borregaard, J.; Skov, L.; Wang, L.; Ting, N.; Wang, C.; Beck, L. A.; Sonne, J.; Clucas, A. Evaluation of the effect of the specific CCR1 antagonist CP-481715 on the clinical and cellular responses observed following epicutaneous nickel challenge in human subjects Contact Dermatitis 2008, 59, 212-219
    • (2008) Contact Dermatitis , vol.59 , pp. 212-219
    • Borregaard, J.1    Skov, L.2    Wang, L.3    Ting, N.4    Wang, C.5    Beck, L.A.6    Sonne, J.7    Clucas, A.8
  • 16
    • 74949096245 scopus 로고    scopus 로고
    • AZD-4818, a chemokine CCR1 antagonist: WO2008103126 and WO2009011653
    • Structure suggested from a patent analysis, as described in: Norman, P. AZD-4818, a chemokine CCR1 antagonist: WO2008103126 and WO2009011653 Expert Opin. Ther. Pat. 2009, 19, 1629-1633
    • (2009) Expert Opin. Ther. Pat. , vol.19 , pp. 1629-1633
    • Norman, P.1
  • 18
    • 84907467954 scopus 로고    scopus 로고
    • United States National Library of Medicine lists AZD-4818 as having the CAS number 1003566-93-5: (accessed April 28).
    • United States National Library of Medicine lists AZD-4818 as having the CAS number 1003566-93-5: http://chem.sis.nlm.nih.gov/chemidplus/rn/1003566-93-5 (accessed April 28, 2014).
    • (2014)
  • 19
    • 84866691792 scopus 로고    scopus 로고
    • Computational studies of the binding modes of CCR1 antagonists
    • Liu, Y.; Chen, B.; Wei, J. Computational studies of the binding modes of CCR1 antagonists Mol. Simul. 2012, 38, 953-960
    • (2012) Mol. Simul. , vol.38 , pp. 953-960
    • Liu, Y.1    Chen, B.2    Wei, J.3
  • 20
    • 77955664554 scopus 로고    scopus 로고
    • Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients
    • Kerstjens, H. A.; Bjermer, L.; Eriksson, L.; Dahlstrom, K.; Vestbo, J. Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients Respir. Med. 2010, 104, 1297-1303
    • (2010) Respir. Med. , vol.104 , pp. 1297-1303
    • Kerstjens, H.A.1    Bjermer, L.2    Eriksson, L.3    Dahlstrom, K.4    Vestbo, J.5
  • 21
    • 76749099255 scopus 로고    scopus 로고
    • Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent CC Chemokine Receptor 1 antagonist
    • Lu, C.; Balani, S. K.; Qian, M. G.; Prakash, S. R.; Ducray, P. S.; von Moltke, L. L. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent CC Chemokine Receptor 1 antagonist J. Pharmacol. Exp. Ther. 2010, 332, 562-568
    • (2010) J. Pharmacol. Exp. Ther. , vol.332 , pp. 562-568
    • Lu, C.1    Balani, S.K.2    Qian, M.G.3    Prakash, S.R.4    Ducray, P.S.5    Von Moltke, L.L.6
  • 22
    • 73249120669 scopus 로고    scopus 로고
    • MLN3897 plus methotrexate in patients with rheumatoid arthritis: Safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study
    • Vergunst, C. E.; Gerlag, D. M.; von Moltke, L.; Karol, M.; Wyant, T.; Chi, X.; Matzkin, E.; Leach, T.; Tak, P. P. MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study Arthritis Rheum. 2009, 60, 3572-3581
    • (2009) Arthritis Rheum. , vol.60 , pp. 3572-3581
    • Vergunst, C.E.1    Gerlag, D.M.2    Von Moltke, L.3    Karol, M.4    Wyant, T.5    Chi, X.6    Matzkin, E.7    Leach, T.8    Tak, P.P.9
  • 23
    • 2942585608 scopus 로고    scopus 로고
    • Chemokine blockade: A new era in the treatment of rheumatoid arthritis?
    • Harringman, J. J.; Tak, P. P. Chemokine blockade: a new era in the treatment of rheumatoid arthritis? Arthritis Res. Ther. 2004, 6, 93-97
    • (2004) Arthritis Res. Ther. , vol.6 , pp. 93-97
    • Harringman, J.J.1    Tak, P.P.2
  • 25
    • 84871081339 scopus 로고    scopus 로고
    • The structure has not been formally disclosed, but several patent applications from Chemocentryx claim a single compound. For example, see: U.S. Patent application US 2010/0173911 A1.
    • The structure has not been formally disclosed, but several patent applications from Chemocentryx claim a single compound. For example, see: Li, L.; Pennell, A. M. K.; Zhang, P. 3-(Imidazolyl)-pyrazolo[3,4b]-pyridines, U.S. Patent application US 2010/0173911 A1.
    • 3-(Imidazolyl)-pyrazolo[3,4b]-pyridines
    • Li, L.1    Pennell, A.M.K.2    Zhang, P.3
  • 27
    • 84907467949 scopus 로고    scopus 로고
    • (accessed Feb. 7). See trial identifiers NCT01027728, Study to evaluate safety and efficacy of CCX 354-C in subjects with rheumatoid arthritis (CARAT-1), and NCT01242917, A study to evaluate the safety and efficacy of CCX354-C in subjects with rheumatoid arthritis partially responsive to methotrexate therapy (CARAT-2).
    • CCX354 is listed as having completed two clinical trials on www.clinicaltrials.gov (accessed Feb. 7, 2013). See trial identifiers NCT01027728, Study to evaluate safety and efficacy of CCX 354-C in subjects with rheumatoid arthritis (CARAT-1), and NCT01242917, A study to evaluate the safety and efficacy of CCX354-C in subjects with rheumatoid arthritis partially responsive to methotrexate therapy (CARAT-2).
    • (2013) CCX354 is Listed As Having Completed Two Clinical Trials on
  • 29
    • 85028106569 scopus 로고    scopus 로고
    • Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial
    • Tak, P. P.; Balanescu, A.; Tseluyko, V. Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial Ann. Rheum. Dis. 2012, 72, 337-344
    • (2012) Ann. Rheum. Dis. , vol.72 , pp. 337-344
    • Tak, P.P.1    Balanescu, A.2    Tseluyko, V.3
  • 33
    • 0036799870 scopus 로고    scopus 로고
    • The nuclear pregnane X receptor: A key regulator of xenobiotic metabolism
    • Kliewer, S.; Goodwin, B.; Willson, T. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism Endocr. Rev. 2002, 23, 687-702
    • (2002) Endocr. Rev. , vol.23 , pp. 687-702
    • Kliewer, S.1    Goodwin, B.2    Willson, T.3
  • 36
    • 0035933511 scopus 로고    scopus 로고
    • The human nuclear xenobiotic receptor PXR: Structural determinants of directed promiscuity
    • Watkins, R. E.; Wisely, G. B.; Moore, L. B. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity Science. 2001, 292, 2329-2333
    • (2001) Science. , vol.292 , pp. 2329-2333
    • Watkins, R.E.1    Wisely, G.B.2    Moore, L.B.3
  • 37
    • 84907451770 scopus 로고    scopus 로고
    • PXR: A xenobiotic receptor of diverse function implicated in pharmacogenetics
    • Gillam, E. M. PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics Trends Pharmacol. Sci. 2001, 22, 448
    • (2001) Trends Pharmacol. Sci. , vol.22 , pp. 448
    • Gillam, E.M.1
  • 40
    • 84907467947 scopus 로고    scopus 로고
    • The PDB deposition number is 4NY9.
    • The PDB deposition number is 4NY9.
  • 41
    • 0031059866 scopus 로고    scopus 로고
    • Processing of X-ray diffraction data collected in oscillation mode
    • Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode Methods Enzymol. 2007, 276, 307-326
    • (2007) Methods Enzymol. , vol.276 , pp. 307-326
    • Otwinowski, Z.1    Minor, W.2
  • 43
    • 33846627754 scopus 로고    scopus 로고
    • Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism
    • Xue, Y.; Chao, E.; Zuercher, W. J.; Willson, T. M.; Collins, J. L.; Redinbo, M. R. Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism Bioorg. Med. Chem. 2007, 15, 2156-2166
    • (2007) Bioorg. Med. Chem. , vol.15 , pp. 2156-2166
    • Xue, Y.1    Chao, E.2    Zuercher, W.J.3    Willson, T.M.4    Collins, J.L.5    Redinbo, M.R.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.